
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5174614/publications.pdf Version: 2024-02-01



WALDEMAD A THOSK

#	Article	IF	CITATIONS
1	The Effect of Thermal Treatment on Selected Properties and Content of Biologically Active Compounds in Potato Crisps. Applied Sciences (Switzerland), 2022, 12, 555.	1.3	5
2	Evidence against involvement of kynurenate branch of kynurenine pathway in pathophysiology of Fuchs' dystrophy and keratoconus. Experimental Eye Research, 2022, 216, 108959.	1.2	1
3	Unexpected content of kynurenine in mother's milk and infant formulas. Scientific Reports, 2022, 12, 6464.	1.6	7
4	HPLC Gradient Retention of Tryptophan and its Metabolites on Three Stationary Phases in Context of Lipophilicity Assessment. Journal of Chromatographic Science, 2021, 59, 40-46.	0.7	2
5	Tryptophan Pathway Abnormalities in a Murine Model of Hereditary Glaucoma. International Journal of Molecular Sciences, 2021, 22, 1039.	1.8	9
6	Tryptophan as a Safe Compound in Topical Ophthalmic Medications: In Vitro and In Vivo Studies. Ocular Immunology and Inflammation, 2021, , 1-11.	1.0	2
7	Effect of 4-week physical exercises on tryptophan, kynurenine and kynurenic acid content in human sweat. Scientific Reports, 2021, 11, 11092.	1.6	11
8	Kynurenic Acid Accelerates Healing of Corneal Epithelium In Vitro and In Vivo. Pharmaceuticals, 2021, 14, 753.	1.7	3
9	Kynurenine emerges from the shadows – Current knowledge on its fate and function. , 2021, 225, 107845.		67
10	Content of tryptophan and kynurenines in serum and milk of dairy cows with mastitis caused by Streptococcus spp Reproduction in Domestic Animals, 2021, , .	0.6	0
11	Propofol and Sevoflurane Anesthesia in Early Childhood Do Not Influence Seizure Threshold in Adult Rats. International Journal of Environmental Research and Public Health, 2021, 18, 12367.	1.2	1
12	Kynurenic acid and cancer: facts and controversies. Cellular and Molecular Life Sciences, 2020, 77, 1531-1550.	2.4	65
13	Phenotypic Characterization of Larval Zebrafish (Danio rerio) with Partial Knockdown of the cacna1a Gene. Molecular Neurobiology, 2020, 57, 1904-1916.	1.9	28
14	Kynurenic acid selectively reduces heart rate in spontaneously hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 673-679.	1.4	15
15	LC-QTOF/MS determination of tryptophan and kynurenine in infant formulas. Journal of Pharmaceutical and Biomedical Analysis, 2020, 191, 113619.	1.4	4
16	Improved Production of Kynurenic Acid by Yarrowia lipolytica in Media Containing Different Honeys. Sustainability, 2020, 12, 9424.	1.6	9
17	P0016EFFECT OF GEMFIBROZIL ON KYNURENINE AMINOTRANSFERASE ACTIVITY AND KYNURENIC ACID PRODUCTION IN RAT KIDNEY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	1
18	The Influence of Palmatine Isolated from Berberis sibirica Radix on Pentylenetetrazole-Induced Seizures in Zebrafish. Cells, 2020, 9, 1233.	1.8	20

#	Article	IF	CITATIONS
19	Lipophilicity of tryptophan, its metabolites and derivatives measured by thin-layer chromatography. Journal of Liquid Chromatography and Related Technologies, 2020, 43, 375-380.	0.5	2
20	AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:―a translational review and therapeutic perspectives. Restorative Neurology and Neuroscience, 2020, 38, 343-354.	0.4	43
21	An efficient method for production of kynurenic acid by Yarrowia lipolytica. Yeast, 2020, 37, 541-547.	0.8	13
22	FP026DICLOFENAC INHIBITS KYNURENINE AMINOTRANSFERASE ACTIVITY AND KYNURENIC ACID PRODUCTION IN RAT KIDNEY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	1
23	Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes. Frontiers in Physiology, 2019, 10, 1254.	1.3	12
24	Changes in tryptophan and kynurenine pathway metabolites in the blood of children treated with ketogenic diet for refractory epilepsy. Seizure: the Journal of the British Epilepsy Association, 2019, 69, 265-272.	0.9	31
25	Kynurenic acid as the neglected ingredient of commercial baby formulas. Scientific Reports, 2019, 9, 6108.	1.6	27
26	Examination of Kynurenine Toxicity on Corneal and Conjunctival Epithelium: In vitro and in vivo Studies. Ophthalmic Research, 2019, 62, 24-35.	1.0	1
27	Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro. Neurotoxicity Research, 2019, 35, 244-254.	1.3	9
28	The presence and distribution of G protein-coupled receptor 35 (GPR35) in the human cornea – Evidences from in silico gene expression analysis and immunodetection. Experimental Eye Research, 2019, 179, 188-192.	1.2	7
29	Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 209-217.	1.4	7
30	Quinaldic acid induces changes in the expression of p53 tumor suppressor both on protein and gene level in colon cancer LS180 cells. Pharmacological Reports, 2019, 71, 189-193.	1.5	4
31	Effect of Kynurenic Acid on Pupae Viability of Drosophila melanogaster cinnabar and cardinal Eye Color Mutants with Altered Tryptophan-Kynurenine Metabolism. Neurotoxicity Research, 2018, 34, 324-331.	1.3	9
32	Quinaldic acid in synovial fluid of patients with rheumatoid arthritis and osteoarthritis and its effect on synoviocytes in vitro. Pharmacological Reports, 2018, 70, 277-283.	1.5	7
33	Kynurenic Acid Protects against Thioacetamide-Induced Liver Injury in Rats. Analytical Cellular Pathology, 2018, 2018, 1-11.	0.7	29
34	Fate and distribution of kynurenic acid administered as beverage. Pharmacological Reports, 2018, 70, 1089-1096.	1.5	18
35	FP036THE INFLUENCE OF CANDESARTAN ON KYNURENIC ACID PRODUCTION IN RAT KIDNEY IN VITRO. Nephrology Dialysis Transplantation, 2018, 33, i59-i59.	0.4	1
36	Tryptophan, kynurenine, kynurenic acid concentrations and indoleamine 2,3â€dioxygenase activity in serum and milk of dairy cows with subclinical mastitis caused by coagulaseâ€negative staphylococci. Reproduction in Domestic Animals, 2018, 53, 1491-1497.	0.6	12

#	Article	IF	CITATIONS
37	The effect of three angiotensin-converting enzyme inhibitors on kynurenic acid production in rat kidney in vitro. Pharmacological Reports, 2017, 69, 536-541.	1.5	8
38	Effects of tryptophan, kynurenine and kynurenic acid exerted on human reconstructed corneal epithelium in vitro. Pharmacological Reports, 2017, 69, 722-729.	1.5	15
39	Influence of picolinic acid on seizure susceptibility in mice. Pharmacological Reports, 2017, 69, 77-80.	1.5	8
40	Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain—Its Possible Clinical Applications. Neurotoxicity Research, 2017, 32, 639-648.	1.3	30
41	Kynurenic Acid Induces Impairment of Oligodendrocyte Viability: On the Role of Glutamatergic Mechanisms. Neurochemical Research, 2017, 42, 838-845.	1.6	7
42	Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye. Current Medicinal Chemistry, 2017, 24, 3547-3558.	1.2	11
43	The presence of kynurenine aminotransferases in the human cornea: Evidence from bioinformatics analysis of gene expression and immunohistochemical staining. Molecular Vision, 2017, 23, 364-371.	1.1	6
44	The effect of kynurenic acid on the synthesis of selected cytokines by murine splenocytes – in vitro and ex vivo studies. Central-European Journal of Immunology, 2016, 1, 39-46.	0.4	23
45	Successful treatment of anti-NMDA receptor encephalitis with a prompt ovarian tumour removal and prolonged course of plasmapheresis: A case report. Molecular and Clinical Oncology, 2016, 5, 845-849.	0.4	6
46	Angiotensin-converting enzyme inhibitors modulate kynurenic acid production in rat brain cortex in vitro. European Journal of Pharmacology, 2016, 789, 308-312.	1.7	9
47	Protective action of nicotinic acid benzylamide in a variety of chemically-induced seizures in mice. Pharmacological Reports, 2016, 68, 297-300.	1.5	2
48	Clonidine decreases kynurenic acid production in rat brain cortex in vitro – a novel antihypertensive mechanism of action?. Journal of Pre-Clinical and Clinical Research, 2016, 10, 57-59.	0.2	0
49	Kynurenic Acid Content in Selected Culinary Herbs and Spices. Journal of Chemistry, 2015, 2015, 1-6.	0.9	21
50	Serum tryptophan and its metabolites in female dogs undergoing ovariohysterectomy as treatment of pyometra or as elective spay surgery. Theriogenology, 2015, 83, 1279-1286.	0.9	11
51	Quinaldic acid inhibits proliferation of colon cancer HT-29 cells in vitro: Effects on signaling pathways. European Journal of Pharmacology, 2015, 757, 21-27.	1.7	12
52	Trace metal analyses in honey samples from selected countries. A potential use in bio-monitoring. International Journal of Environmental Analytical Chemistry, 2015, , 1-12.	1.8	3
53	Prolonged Subdural Infusion of Kynurenic Acid Is Associated with Dose-Dependent Myelin Damage in the Rat Spinal Cord. PLoS ONE, 2015, 10, e0142598.	1.1	17
54	Cholinesterase activity in blood and pesticide presence in sweat as biomarkers of children`s environmental exposure to crop protection chemicals. Annals of Agricultural and Environmental Medicine, 2015, 22, 478-482.	0.5	13

#	Article	IF	CITATIONS
55	Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice. Central-European Journal of Immunology, 2014, 1, 6-13.	0.4	16
56	Kynurenic acid inhibits colon cancer proliferation in vitro: effects on signaling pathways. Amino Acids, 2014, 46, 2393-2401.	1.2	69
57	Effects of systemic administration of kynurenic acid and glycine on renal haemodynamics and excretion in normotensive and spontaneously hypertensive rats. European Journal of Pharmacology, 2014, 743, 37-41.	1.7	23
58	Kynurenic acid inhibits proliferation and migration of human glioblastoma T98G cells. Pharmacological Reports, 2014, 66, 130-136.	1.5	43
59	On the toxicity of kynurenic acid in vivo and in vitro. Pharmacological Reports, 2014, 66, 1127-1133.	1.5	20
60	Orphenadrine-induced convulsive status epilepticus in rats responds to the NMDA antagonist dizocilpine. Pharmacological Reports, 2014, 66, 399-403.	1.5	5
61	Modulation by kynurenine of extracellular kynurenate and glutamate in cerebral cortex of rats with acute liver failure. Pharmacological Reports, 2014, 66, 466-470.	1.5	5
62	Presence and distribution of l-kynurenine aminotransferases immunoreactivity in human cataractous lenses. Acta Ophthalmologica, 2013, 91, e450-e455.	0.6	5
63	Tryptophan-Kynurenine Metabolism and Insulin Resistance in Hepatitis C Patients. Hepatitis Research and Treatment, 2013, 2013, 1-4.	2.0	30
64	Effect of dietary administration of kynurenic acid on the activity of splenocytes of the rainbow trout (Oncorhynchus mykiss). Central-European Journal of Immunology, 2013, 4, 475-479.	0.4	3
65	Kynurenic acid enhances expression of p21 Waf1/Cip1 in colon cancer HT-29 cells. Pharmacological Reports, 2012, 64, 745-750.	1.5	30
66	Main dietary compounds and pancreatic cancer risk. The quantitative analysis of case–control and cohort studies. Cancer Epidemiology, 2012, 36, 60-67.	0.8	63
67	Kynurenic acid in human renal cell carcinoma: its antiproliferative and antimigrative action on Caki-2 cells. Amino Acids, 2012, 43, 1663-1670.	1.2	41
68	Potato- An Important Source of Nutritional Kynurenic Acid. Plant Foods for Human Nutrition, 2012, 67, 17-23.	1.4	41
69	Ketogenic diet increases concentrations of kynurenic acid in discrete brain structures of young and adult rats. Journal of Neural Transmission, 2012, 119, 679-684.	1.4	25
70	A ketogenic diet may offer neuroprotection in glaucoma and mitochondrial diseases of the optic nerve. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2012, 1, 45-9.	0.4	10
71	Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scandinavian Journal of Gastroenterology, 2011, 46, 903-912.	0.6	68
72	Kynurenic acid and kynurenine aminotransferases in retinal aging and neurodegeneration. Pharmacological Reports, 2011, 63, 1324-1334.	1.5	12

#	Article	IF	CITATIONS
73	Nefopam enhances the protective activity of antiepileptics against maximal electroshockinduced convulsions in mice. Pharmacological Reports, 2011, 63, 690-696.	1.5	5
74	Orphenadrine induces secondarily generalized convulsive status epilepticus in rats. Brain Research Bulletin, 2011, 84, 389-393.	1.4	4
75	Distribution, Synthesis, and Absorption of Kynurenic Acid in Plants. Planta Medica, 2011, 77, 858-864.	0.7	39
76	Presence of L-kynurenine aminotransferase III in retinal ganglion cells and corpora amylacea in the human retina and optic nerve. , 2011, 49, 132-7.		3
77	Neuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat—possible involvement of kynurenic acid. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 1729-1735.	1.0	34
78	Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients. Leukemia Research, 2010, 34, 38-45.	0.4	6
79	Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. Epilepsy Research, 2010, 88, 269-274.	0.8	13
80	Long-term exposure to nicotine markedly reduces kynurenic acid in rat brain — In vitro and ex vivo evidence. Toxicology and Applied Pharmacology, 2009, 240, 174-179.	1.3	9
81	Presence of kynurenic acid in food and honeybee products. Amino Acids, 2009, 36, 75-80.	1.2	88
82	High concentration of kynurenic acid in bile and pancreatic juice. Amino Acids, 2009, 37, 637-641.	1.2	41
83	Kynurenic acid protects against the homo-cysteine-induced impairment of endothelial cells. Pharmacological Reports, 2009, 61, 751-756.	1.5	32
84	Influence of orphenadrine upon the protective activity of various antiepileptics in the maximal electroshock-induced convulsions in mice. Pharmacological Reports, 2009, 61, 732-736.	1.5	5
85	Micromolar concentration of kynurenic acid in rat small intestine. Amino Acids, 2008, 35, 503-505.	1.2	85
86	Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Annals of Neurology, 2008, 64, 434-445.	2.8	157
87	Anticonvulsant and acute adverse effect profiles of picolinic acid 2-fluoro-benzylamide in various experimental seizure models and chimney test in mice. Fundamental and Clinical Pharmacology, 2008, 22, 69-74.	1.0	18
88	Elevated Concentrations of Kynurenic Acid, a Tryptophan Derivative, in Dense Nuclear Cataracts. Current Eye Research, 2007, 32, 27-32.	0.7	24
89	Characterization of the anticonvulsant profile of isonicotinic acid benzylamide in various experimental seizure models in mice. Neuroscience Letters, 2007, 421, 87-90.	1.0	4
90	Lithium–methomyl induced seizures in rats: A new model of status epilepticus?. Toxicology and Applied Pharmacology, 2007, 219, 122-127.	1.3	4

#	Article	IF	CITATIONS
91	NMDA antagonists exert distinct effects in experimental organophosphate or carbamate poisoning in mice. Toxicology and Applied Pharmacology, 2007, 219, 114-121.	1.3	31
92	Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. Journal of Neural Transmission, 2007, 114, 1011-1015.	1.4	56
93	Ammonia at pathophysiologically relevant concentrations activates kynurenic acid synthesis in cultured astrocytes and neurons. NeuroToxicology, 2006, 27, 619-622.	1.4	5
94	Kynurenic acid synthesis in bovine retinal slices – effect of glutamate agonists. Journal of Neural Transmission, 2006, 113, 1367-1372.	1.4	2
95	Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro. Rheumatology International, 2006, 26, 422-426.	1.5	39
96	Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro. European Journal of Pharmacology, 2006, 535, 95-97.	1.7	16
97	Enhancement of brain kynurenic acid production by anticonvulsants—Novel mechanism of antiepileptic activity?. European Journal of Pharmacology, 2006, 541, 147-151.	1.7	30
98	A selective method for transfection of retinal ganglion cells by retrograde transfer of antisense oligonucleotides against kynurenine aminotransferase II. Molecular Vision, 2006, 12, 100-7.	1.1	9
99	Kynurenic acid in human salivadoes it influence oral microflora?. Pharmacological Reports, 2006, 58, 393-8.	1.5	26
100	Anticonvulsant and acute neurotoxic characteristics of nicotinic acid benzylamide: a preclinical study. Pharmacological Reports, 2006, 58, 431-4.	1.5	5
101	Dual effect ofDL-homocysteine andS-adenosylhomocysteine on brain synthesis of the glutamate receptor antagonist, kynurenic acid. Journal of Neuroscience Research, 2005, 79, 375-382.	1.3	37
102	Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons. Journal of Neuroscience Research, 2005, 80, 677-682.	1.3	26
103	Demonstration of Kynurenine Aminotransferases I and II and Characterization of Kynurenic Acid Synthesis in Oligodendrocyte Cell Line (OLN-93). Neurochemical Research, 2005, 30, 963-968.	1.6	31
104	Effect of pesticides on kynurenic acid production in rat brain slices. Annals of Agricultural and Environmental Medicine, 2005, 12, 177-9.	0.5	5
105	Content of Kynurenic Acid and Activity of Kynurenine Aminotransferases in Mammalian Eyes. Ophthalmic Research, 2004, 36, 124-128.	1.0	18
106	Carbamazepine enhances brain production of kynurenic acid in vitro. European Journal of Pharmacology, 2004, 498, 325-326.	1.7	10
107	Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 300-304.	1.4	21
108	Kynurenic acid synthesis in cerebral cortical slices of rats with progressing symptoms of thioacetamide-induced hepatic encephalopathy. Journal of Neuroscience Research, 2004, 75, 436-440.	1.3	25

#	Article	IF	CITATIONS
109	Ethosuximide and valproate display high efficacy against lindane-induced seizures in mice. Toxicology Letters, 2004, 154, 55-60.	0.4	10
110	Expression of kynurenine aminotransferases in the rat retina during development. Vision Research, 2004, 44, 1-7.	0.7	8
111	Age-dependent decrease of retinal kynurenate and kynurenine aminotransferases in DBA/2J mice, a model of ocular hypertension. Vision Research, 2004, 44, 655-660.	0.7	14
112	Geographical Information System (GIS) as a tool for monitoring and analysing pesticide pollution and its impact on public health. Annals of Agricultural and Environmental Medicine, 2004, 11, 181-4.	0.5	20
113	Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2003, 107, 412-418.	1.0	61
114	Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage. Vision Research, 2003, 43, 497-503.	0.7	23
115	Ontogenic changes of kynurenine aminotransferase I activity and its expression in the chicken retina. Vision Research, 2003, 43, 1513-1517.	0.7	11
116	l-Cysteine sulphinate, endogenous sulphur-containing amino acid, inhibits rat brain kynurenic acid production via selective interference with kynurenine aminotransferase II. Neuroscience Letters, 2003, 346, 97-100.	1.0	49
117	Dizocilpine Improves Beneficial Effects of Cholinergic Antagonists in Anticholinesterase-Treated Mice. Toxicological Sciences, 2003, 72, 289-295.	1.4	17
118	FK506 attenuates 1-methyl-4-phenylpyridinium- and 3-nitropropionic acid-evoked inhibition of kynurenic acid synthesis in rat cortical slices. Acta Neurobiologiae Experimentalis, 2003, 63, 101-8.	0.4	4
119	Nicotine diminishes anticonvulsant activity of antiepileptic drugs in mice. Polish Journal of Pharmacology, 2003, 55, 799-802.	0.3	11
120	Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neuroscience Letters, 2002, 331, 63-65.	1.0	87
121	1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. Neuroscience Letters, 2002, 330, 49-52.	1.0	53
122	Regulation of kynurenic acid synthesis in C6 glioma cells. Journal of Neuroscience Research, 2002, 68, 622-626.	1.3	18
123	Changes of kynurenic acid content in the rat and chicken retina during ontogeny. , 2002, 240, 687-691.		11
124	The use of the radioisotope method in studies of pesticide penetration into the eyeball. Annals of Agricultural and Environmental Medicine, 2002, 9, 29-31.	0.5	1
125	Protective effect of adenosine receptor agonists in a new model of epilepsy – seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice. Neuroscience Letters, 2001, 305, 91-94.	1.0	26
126	Presence of kynurenic acid and kynurenine aminotransferases in the inner retina. NeuroReport, 2001, 12, 3675-3678.	0.6	22

#	Article	IF	CITATIONS
127	Amino Acid Derivatives with Anticonvulsant Activity Chemical and Pharmaceutical Bulletin, 2001, 49, 629-631.	0.6	16
128	Evidence for Intraocular Synthesis of Kynurenic Acid, a Putative Endogenous Neuroprotectant. Ophthalmic Research, 2001, 33, 107-110.	1.0	5
129	On the interactions between antimuscarinic atropine and NMDA receptor antagonists in anticholinesterase-treated mice. Archives of Toxicology, 2001, 74, 702-708.	1.9	23
130	Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-induced seizures. Pharmacology Biochemistry and Behavior, 2001, 68, 661-668.	1.3	28
131	AMPA and GABAB receptor antagonists and their interaction in rats with a genetic form of absence epilepsy. European Journal of Pharmacology, 2001, 430, 251-259.	1.7	37
132	Kynurenine Aminotransferase I Activity in Human Placenta. Placenta, 2001, 22, 259-261.	0.7	15
133	Formation of endogenous glutamatergic receptors antagonist kynurenic acid — differences between cortical and spinal cord slices. Brain Research, 2000, 878, 210-212.	1.1	24
134	Proconvulsive effects of the mitochondrial respiratory chain inhibitor — 3-nitropropionic acid. European Journal of Pharmacology, 2000, 403, 229-233.	1.7	8
135	Protection by conventional and new antiepileptic drugs against lindane-induced seizures and lethal effects in mice. Neurotoxicity Research, 2000, 2, 63-70.	1.3	10
136	NMDA- But Not Kainate-Mediated Events Reduce Efficacy of Some Antiepileptic Drugs Against Generalized Tonic-Clonic Seizures in Mice. Epilepsia, 1999, 40, 1507-1511.	2.6	5
137	AMPA/kainate-related mechanisms contribute to convulsant and proconvulsant effects of 3-nitropropionic acid. European Journal of Pharmacology, 1999, 370, 251-256.	1.7	14
138	Intrapartum levels of endogenous glutamate antagonist-kynurenic acid in amniotic fluid, umbilical and maternal blood. Neuroscience Research Communications, 1999, 24, 173-178.	0.2	18
139	Excitatory Amino Acid Antagonists Alleviate Convulsive and Toxic Properties of Lindane in Mice. Basic and Clinical Pharmacology and Toxicology, 1998, 82, 137-141.	0.0	12
140	Acute ammonia treatment in vitro and in vivo inhibits the synthesis of a neuroprotectant kynurenic acid in rat cerebral cortical slices. Brain Research, 1998, 787, 348-350.	1.1	18
141	Felbamate demonstrates low propensity for interaction with methylxanthines and Ca2+ channel modulators against experimental seizures in mice. European Journal of Pharmacology, 1998, 352, 207-214.	1.7	12
142	Mitochondrial toxin 3-nitropropionic acid evokes seizures in mice. European Journal of Pharmacology, 1998, 359, 55-58.	1.7	43
143	A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. European Neuropsychopharmacology, 1998, 8, 233-238.	0.3	1
144	EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON THE ANTICONVULSIVE ACTIVITY OF VALPROATE AND DIPHENYLHYDANTOIN AGAINST MAXIMAL ELECTROSHOCK-INDUCED SEIZURES IN MICE. Pharmacological Research, 1998, 37, 375-381.	3.1	22

#	Article	IF	CITATIONS
145	Chlormethiazole anticonvulsive efficacy diminished by N-methyl-d-aspartate but not kainate in mice. European Journal of Pharmacology, 1998, 345, 257-260.	1.7	4
146	Glutamatergic Receptor Agonists and Brain Pathology. , 1998, , 329-354.		6
147	Impairment of brain kynurenic acid production by glutamate metabotropic receptor agonists. NeuroReport, 1997, 8, 3501-3505.	0.6	40
148	Brainâ€Specific Modulation of Kynurenic Acid Synthesis in the Rat. Journal of Neurochemistry, 1997, 69, 290-298.	2.1	91
149	Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs. Metabolic Brain Disease, 1996, 11, 143-152.	1.4	22
150	Interaction of Calcium Channel Blockers and Excitatory Amino Acid Antagonists with Conventional Antiepileptic Drugs. CNS Neuroscience & Therapeutics, 1996, 2, 452-467.	4.0	15
151	Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice. European Journal of Pharmacology, 1995, 281, 327-333.	1.7	29
152	The competitive NMDA antagonist, D-CPP-ene, potentiates the anticonvulsant activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. Neuropharmacology, 1994, 33, 619-624.	2.0	28
153	Influence of a Ca2+ channel agonist, BAY k-8644, on the anticonvulsant activity of NMDA and non-NMDA receptor antagonists. European Journal of Pharmacology, 1994, 264, 103-106.	1.7	17
154	Towards an understanding of the role of glutamate in neurodegenerative disorders: energy metabolism and neuropathology. Experientia, 1993, 49, 1064-1072.	1.2	84
155	2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology, 1993, 32, 895-900.	2.0	49
156	Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics. European Journal of Pharmacology, 1993, 250, 1-7.	1.7	25
157	Competitive antagonist of NMDA receptors, CGP 37849 and CGP 39551, enhance the anticonvulsant activity of valproate against electroconvulsions in mice. European Journal of Pharmacology, 1993, 232, 59-64.	1.7	29
158	NBQX does not affect learning and memory tasks in mice: a comparison with D-CPPene and ifenprodil. Cognitive Brain Research, 1992, 1, 67-71.	3.3	41
159	Kynurenic Acid: A Potential Pathogen in Brain Disorders. Annals of the New York Academy of Sciences, 1992, 648, 140-153.	1.8	69
160	Age dependency of the susceptibility of rats to aminooxyacetic acid seizures. Developmental Brain Research, 1992, 67, 137-144.	2.1	8
161	Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. Neuropharmacology, 1992, 31, 1021-1026.	2.0	28
162	Age-related changes in kynurenic acid production in rat brain. Brain Research, 1992, 588, 1-5.	1.1	84

#	Article	IF	CITATIONS
163	Quinolinate-like neurotoxicity produced by aminooxyacetic acid in rat striatum. Amino Acids, 1992, 2, 245-253.	1.2	2
164	Influence of MK-801 on the anticonvulsant activity of antiepileptics. European Journal of Pharmacology, 1991, 200, 277-282.	1.7	36
165	Systemic kainic acid administration in rats: Effects on kynurenic acid production in vitro and in vivo. Experimental Neurology, 1991, 113, 47-52.	2.0	18
166	Paradoxical anticonvulsant acitivity of the ?hyphen;Aminobutyrate antagonist bicuculline methiodide in the rat striatum. Synapse, 1991, 7, 14-20.	0.6	26
167	Seizures induced by aminooxyacetic acid in mice: Pharmacolgical characteristics. Synapse, 1991, 7, 173-180.	0.6	23
168	Aminooxyacetic acid produces excitotoxic lesions in the rat striatum. Synapse, 1991, 9, 129-135.	0.6	58
169	Longâ€Term Effects of Pilocarpine in Rats: Structural Damage of the Brain Triggers Kindling and Spontaneous I Recurrent Seizures. Epilepsia, 1991, 32, 778-782.	2.6	555
170	Dopamine control of seizure propagation: Intranigral dopamine D1 agonist SKF-38393 enhances susceptibility of seizures. Synapse, 1990, 5, 113-119.	0.6	83
171	Substantia nigra: A site of action of muscle relaxant drugs. Annals of Neurology, 1990, 28, 341-348.	2.8	26
172	Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: Effect of aminooxyacetic acid. Neuroscience Letters, 1990, 116, 198-203.	1.0	56
173	Excitatory amino acid antagonists and memory: Effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks. Neuropharmacology, 1990, 29, 1111-1116.	2.0	168
174	Excitatory amino acid antagonists protect mice against seizures induced by bicuculline. Brain Research, 1990, 514, 131-134.	1.1	48
175	The entopeduncular nucleus regulates muscle tone in genetically spastic rats: role of substance P and Î ³ -aminobutyric acid. Brain Research, 1990, 509, 347-350.	1.1	5
176	Blockade of excitatory neurotransmission in the globus pallidus induces rigidity and akinesia in the rat: implications for excitatory neurotransmission in pathogenesis of Parkinson's diseases. Brain Research, 1990, 512, 125-131.	1.1	38
177	Excitatory amino acid antagonists and memory: Effect of drugs acting at N- methyl-D-aspartate receptors in learning and memory tasks. , 1990, , 745-753.		1
178	Review: Cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: A novel experimental model of intractable epilepsy. Synapse, 1989, 3, 154-171.	0.6	586
179	Rat Brain Slices Produce and Liberate Kynurenic Acid upon Exposure to l-Kynurenine. Journal of Neurochemistry, 1989, 52, 1629-1636.	2.1	198
180	Homocysteic acid: convulsant action of stereoisomers in mice. Brain Research, 1989, 479, 371-373.	1.1	34

#	Article	IF	CITATIONS
181	On the disposition of intrahippocampally injected kynurenic acid in the rat. Experimental Brain Research, 1988, 71, 563-567.	0.7	53
182	Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats. Brain Research, 1988, 462, 275-285.	1.1	29
183	Identification and quantification of kynurenic acid in human brain tissue. Brain Research, 1988, 454, 164-169.	1.1	203
184	Effect of Aminophylline and Enprofylline on the Protective Efficacy of Common Antiepileptic Drugs Against Electroconvulsions in Mice. Epilepsia, 1987, 28, 383-386.	2.6	23
185	The susceptibility of rats to pilocarpine-induced seizures is age-dependent. Developmental Brain Research, 1987, 37, 43-58.	2.1	276
186	Evidence that antagonism at non-NMDA receptors results in anticonvulsant action. European Journal of Pharmacology, 1987, 136, 69-73.	1.7	27
187	Effects ofl-cysteine-sulphinate andl-aspartate, mixed excitatory amino acid agonists, on the membrane potential of cat caudate neurons. Brain Research, 1987, 414, 330-338.	1.1	17
188	Substantia nigra and motor control in the rat: effect of intranigral α-kainate and γ-d-glutamylaminomethylsulphonate on motility. Brain Research, 1987, 424, 37-48.	1.1	23
189	Only certain antiepileptic drugs prevent seizures induced by pilocarpine. Brain Research Reviews, 1987, 12, 281-305.	9.1	91
190	Convulsant action of morphine, [d-ala2, d-leu5]-enkephalin and naloxone in the rat amygdala: Electroencephalographic, morphological and behavioural sequelae. Neuroscience, 1987, 20, 671-686.	1.1	28
191	Seizures produced by pilocarpine: Neuropathological sequelae and activity of glutamate decarboxylase in the rat forebrain. Brain Research, 1986, 398, 37-48.	1.1	104
192	Excitatory neurotransmission within substantia nigra pars reticulata regulates threshold for seizures produced by pilocarpine in rats: Effects of intranigral 2-amino-7-phosphonoheptanoate and n-methyl-d-aspartate. Neuroscience, 1986, 18, 61-77.	1.1	138
193	Susceptibility to seizures produced by pilocarpine in rats after microinjection of isonnazid or \hat{I}^3 -vinyl-GABA into the substantia nigra. Brain Research, 1986, 370, 294-309.	1.1	103
194	Effect of Aminophylline on the Protective Action of Common Antiepileptic Drugs Against Electroconvulsions in Mice. Epilepsia, 1986, 27, 204-208.	2.6	45
195	Aminophylline and CGS 8216 Reverse the Protective Action of Diazepam Against Electroconvulsions in Mice. Epilepsia, 1985, 26, 693-696.	2.6	32
196	Injections of picrotoxin and bicuculline into the amygdaloid complex of the rat: An electroencephalographic, behavioural and morphological analysis. Neuroscience, 1985, 14, 37-53.	1.1	73
197	Muscle relaxant action of excitatory amino acid antagonists. Neuroscience Letters, 1985, 53, 321-326.	1.0	124
198	Muscle relaxant action of 2-chloroadenosine in genetically spastic rats is independent of Î ³ -aminobutyric acid-mediated inhibition. Neuroscience Letters, 1985, 54, 369-374.	1.0	5

#	Article	IF	CITATIONS
199	Phosphonic analogues of excitatory amino acids raise the threshold for maximal electroconvulsions in mice. Neuroscience Research, 1985, 3, 86-90.	1.0	32
200	Modification of the anticonvulsant activity of 2-amino-5-phosphonovalerate by agents affecting different neurotransmitter systems. Neuropharmacology, 1985, 24, 965-968.	2.0	8
201	Effects of aminophylline and 2-chloroadenosine on seizures produced by pilocarpine in rats: Morphological and electroencephalographic correlates. Brain Research, 1985, 361, 309-323.	1.1	70
202	Effects of morphine and naloxone on pilocarpine-induced convulsions in rats. Neuropeptides, 1985, 5, 315-318.	0.9	15
203	Effects of excitatory amino-acid antagonists on the anticonvulsant action of phenobarbital or diphenylhydanton in mice. European Journal of Pharmacology, 1984, 100, 357-362.	1.7	43
204	Effect of aminophylline on muscle relaxant action of diazepam and phenobarbitone in genetically spastic rats: Further evidence for a purinergic mechanism in the action of diazepam. European Journal of Pharmacology, 1984, 103, 99-105.	1.7	11
205	A specific benzodiazepine antagonist CGS 8216 reverses the muscle relaxant effect of diazepam but not that of phenobarbitone. European Journal of Pharmacology, 1984, 98, 441-444.	1.7	11
206	Differential effects of baclofen, Â ³ -hydroxybutyric acid and muscimol on the protective action of phenobarbital and diphenylhydantoin against maximal electroshock-induced seizures in mice. Neuropharmacology, 1984, 23, 159-163.	2.0	19
207	Seizures produced by pilocarpine in mice: A behavioral, electroencephalographic and morphological analysis. Brain Research, 1984, 321, 237-253.	1.1	332
208	Studies on the Mechanism of Wet Dog Shakes Produced by Carbachol in Rats. Pharmacology, 1984, 28, 112-120.	0.9	9
209	Cholinomimetics produce seizures and brain damage in rats. Experientia, 1983, 39, 1408-1411.	1.2	181
210	Limbic seizures produced by pilocarpine in rats: Behavioural, electroencephalographic and neuropathological study. Behavioural Brain Research, 1983, 9, 315-335.	1.2	973
211	Intrahippocampal bethanechol in rats: Behavioural, electroencephalographic and neuropathological correlates. Behavioural Brain Research, 1983, 7, 361-370.	1.2	35
212	Induction of Wet Dog Shakes by Intracerebroventricular Bethanechol in Rats. Pharmacology, 1982, 24, 105-110.	0.9	8
213	Dyphenylhydantoin enhancement of diazepam effects on locomotor activity in mice. Psychopharmacology, 1982, 76, 198-200.	1.5	10
214	Effect of antidepressant drugs on carbachol chloride-induced wet dog shake behaviour in rats. Neuropharmacology, 1981, 20, 1193-1196.	2.0	3
215	Effects of Some Antiepileptic Drugs in Pentetrazol-Induced Convulsions in Mice Lesioned with Kainic Acid. Epilepsia, 1981, 22, 407-414.	2.6	18
216	Evidence against the involvement of serotonergic mechanisms in wet dog shake behavior induced by carbachol chloride in rats. Psychopharmacology, 1981, 73, 376-380.	1.5	12

#	Article	IF	CITATIONS
217	Studies of carbachol-induced wet-dog shake behavior in rats. Psychopharmacology, 1981, 73, 81-83.	1.5	17
218	Effects of morphine and nalorphine on kainic acid-induced hypothermia in rats. Psychopharmacology, 1981, 72, 211-214.	1.5	3
219	(RS)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid: Wet dog shakes, catalepsy and body temperature changes in rats. Pharmacology Biochemistry and Behavior, 1981, 15, 545-549.	1.3	15